SMU Medical Journal

Open Access Open Access  Restricted Access Subscription Access

Benefits and Risk of Topical Corticosteroids in the Management of Ocular Inflammation


Affiliations
1 Department of Ophthalmology, Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, Gangtok, Sikkim, India
 

Ocular inflammations need to be managed at the earliest stage to minimizedamages todelicate oculartissueand to prevent loss of vision. Topical steroids are the strongest and fastest acting antiinflammatory agent to control ocular inflammation and should be used judiciously to attain maximum benefits without any side effects.

Keywords

Ocular Inflammation, Topical Corticosteroid.
User
Notifications
Font Size

  • Abelson MB, Butrus S. Corticosteroids in ophthalmic practice. Chapter 23. (2008) In: Albert DM et al., eds.Albert&Jakobiec;’s Principles and Practice of Ophthalmology, 3rd ed. Philadelphia: Saunders Elsevier.

  • Rev Med Interne. 2013 May;34 (5):25863.doi: 10.1016/j.revmed.2012.12.009. Epub 2013 Jan 14.

  • Jaanus SD, Cheetham JK, Lesher GA.(2001) Anti-inflammatory drugs. In: Bartlett JD, Jaanus SD, eds.Clinical Ocular Pharmacology, 4th ed. Boston: Butterworth, 273-276.

  • Angra S K. Ophthalmic use of topical corticosteroids. (1982) Indian J Ophthalmol [serial online] [cited 2015 May 9];30:213218

  • Abelson M, Sleeper A. (2005) Insights on anti-inflammatories. Rev Ophthalmol. 12(6):80-4.

  • McGhee CNJ. (1992) Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol. 76:681-4.

  • Duvall B, Kershner R. (2006) Ophthalmic Medications and Pharmacology, 2nd ed. Thorofare, N.J.: Slack..

  • El-Harazi SM, Feldman RM.(2001) CurrOpinOphthalmol. 12(1):4-8.

  • Srinivasan M et al. (2012) Arch Ophthalmol.130(2):151-157.

  • Samudre SS et al. J (2004) OculPharmacolTher.20(6):533-547.(table)

  • Armaly MF, Becker B.(1965) Intraocular pressure response to topical corticosteroids. Fed Proc. Nov- Dec;24(6):1274-8

  • Chang DF, Tan JJ, Tripodis Y. (2011) Risk factors for steroid response among cataract patients. J Cataract Refract Surg. 37:675-81.

  • Jones III R, Rhee DJ.(2006) Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. CurrOpinOphthalmol. 17:163167.

  • Tanuj Dada, Soman Nair, MunishDhawan. (2009) Steroid-induced Glaucoma Journal of Current Glaucoma Practice, May-August 3(2):33-38

  • Cohen A. Steroid induced glaucoma. In: Rumelt S, ed. Glaucoma-Basic and Clinical Concepts. (http://www.intechopen.com/books/glaucoma-basic-and-clinicalconcepts/ steroid-induced-glaucoma)

  • Flach AJ, (2002) Topical nonsteroidalantiinflammatory drugs in ophthalmology, IntOphthalmolClin, 42:1–11.

  • Cho H, Wolf KJ, Wolf EJ. (2009) Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution, ClinOphthalmol, 3:199–210

  • Kessel et al. (2014) Topical Steroids versus NSAIDs after Cataract Surgery Ophthalmology 121:1915-1924 ª 2014 by the American Academy of Ophthalmology

  • Gulkilik G, Kocabora S, Taskapili M, Engin G.(2006) Cystoid macular edema after phacoemulsification: risk factors and effecton visual acuity. Can J Ophthalmol 41:699–703.

  • Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. (1999) Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J Cataract Refract Surg 25:1492–7

  • Shimazaki J, Iseda A, Satake Y, Shimazaki-Den S. (2012) Efficacy and safety of long term corticosteroid eye drops after penetrating keratoplasty. Ophthalmology. 119:668-73.

  • Topical steroid, NSAID, antibiotic an ideal therapy before cataract surgery | Ocular Surgery News.

  • Ilyas H, Slonim CB, Braswell GR, et al.(2004) Longterm safety of loteprednoletabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens. 30 (1): 103.

  • Hogan MJ. (1953) Atopic keratoconjunctivitis. Am J Ophthalmol. 36:937947.

  • Bielory BP, Perez VL, Bielory L. (2010) Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in CurrOpin Allergy Clin.Immunol. 10 (5):46977.

  • Wilkins MR, Khan S, Bunce C, Khawaja A, Siriwardena D, Larkin DFP. (2011) A randomized placebo-controlled trial of topical steroids in presumed viral conjunctivitis. Br J Ophthalmology 95:1299-1303.

  • Epidemic Keratoconjunctivitis Treatment &Management;http://emedicine medscape.com/’article’/1192751.

  • Andria M. at el. (2013) Epidemic keratoconjunctivitis: A review of current concepts in management; J Optom. 06:6974 Vol. 06 Num.02 DOI: 10.1016/j.optom.2012.08.003

  • Donshik PC, Suchecki JK, Ehlers WH. (1995) Peripheral corneal infiltrates associated with contact lens wear. Trans Am Ophthalmol Soc. 93:49-60.

  • Wilhelmus KR, Gee L, Hauck WW, et al. (1994) Herpetic Eye Disease Study.Acontrolled trial of topical corticosteroids for herpes simplex stromal keratitis.Ophthalmology.

  • Comstock TL, DeCory HH. (2012) Advances in corticosteroid therapy for ocular inflammationloteprednoletabonate. Int J Inflamm. Article ID 789623.

  • Sheppard JD, Donnenfeld ED. (2008) Topical loteprednol 0.5% induction therapy improves topicalcyclosporine emulsion tolerability in chronic dry eye disease.InvestOphthalmol Vis Sci.49:EAbstract 99.

  • Foster CS, Maza MS. (1994) The Sclera. SpringerVerlag :96102.

  • Lim L, Suhler EB, Smith JR. (2006) Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol. May-Jun 34(4):365-374

  • Optometric Clinical Practice Guideline Care of the Patient with Anterior Uveitis. St. Louis, MO: American Optometric Association; 1994, reviewed 2004:21.

  • Cunningham ET, Wender JD. (2010) Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol. 45;352-8.

  • Foster CS. Uveitis. (2002) Lecture presented at annual meeting of American Academy of Ophthalmology, New Orleans, LA.

  • Heier JS, Topping TM, (2002) Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema.Ophthalmology. 107(11):2034-8;discussion 2039


Abstract Views: 178

PDF Views: 91




  • Benefits and Risk of Topical Corticosteroids in the Management of Ocular Inflammation

Abstract Views: 178  |  PDF Views: 91

Authors

Ajit Kumar Hazarika
Department of Ophthalmology, Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, Gangtok, Sikkim, India

Abstract


Ocular inflammations need to be managed at the earliest stage to minimizedamages todelicate oculartissueand to prevent loss of vision. Topical steroids are the strongest and fastest acting antiinflammatory agent to control ocular inflammation and should be used judiciously to attain maximum benefits without any side effects.

Keywords


Ocular Inflammation, Topical Corticosteroid.

References